JP5051865B2 - レシチンでのプロドラッグエステル非乳化調合物の経口バイオアベイラビリティの向上 - Google Patents

レシチンでのプロドラッグエステル非乳化調合物の経口バイオアベイラビリティの向上 Download PDF

Info

Publication number
JP5051865B2
JP5051865B2 JP2002592867A JP2002592867A JP5051865B2 JP 5051865 B2 JP5051865 B2 JP 5051865B2 JP 2002592867 A JP2002592867 A JP 2002592867A JP 2002592867 A JP2002592867 A JP 2002592867A JP 5051865 B2 JP5051865 B2 JP 5051865B2
Authority
JP
Japan
Prior art keywords
lecithin
cefditoren pivoxil
group
composition
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002592867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005515155A (ja
JP2005515155A5 (enExample
Inventor
タネフア，ラジニーシ
ブリンカー，デール
ブリスキン，ジヤツクリン
ビシユワシラオ，デイリツプ
アポンテ，ロベルト
グプタ，プラムド
Original Assignee
タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド filed Critical タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド
Publication of JP2005515155A publication Critical patent/JP2005515155A/ja
Publication of JP2005515155A5 publication Critical patent/JP2005515155A5/ja
Application granted granted Critical
Publication of JP5051865B2 publication Critical patent/JP5051865B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002592867A 2001-05-29 2002-05-28 レシチンでのプロドラッグエステル非乳化調合物の経口バイオアベイラビリティの向上 Expired - Fee Related JP5051865B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86735301A 2001-05-29 2001-05-29
US29414101P 2001-05-29 2001-05-29
US60/294,141 2001-05-29
US09/867,353 2001-05-29
PCT/US2002/016428 WO2002096354A2 (en) 2001-05-29 2002-05-28 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin

Publications (3)

Publication Number Publication Date
JP2005515155A JP2005515155A (ja) 2005-05-26
JP2005515155A5 JP2005515155A5 (enExample) 2006-01-05
JP5051865B2 true JP5051865B2 (ja) 2012-10-17

Family

ID=26968357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002592867A Expired - Fee Related JP5051865B2 (ja) 2001-05-29 2002-05-28 レシチンでのプロドラッグエステル非乳化調合物の経口バイオアベイラビリティの向上

Country Status (5)

Country Link
EP (1) EP1401402B1 (enExample)
JP (1) JP5051865B2 (enExample)
CA (1) CA2449002C (enExample)
MX (1) MXPA03010945A (enExample)
WO (1) WO2002096354A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500712C (en) * 2002-10-02 2011-08-09 Meiji Seika Kaisha, Ltd. Antibiotic pharmaceutical composition with improved oral absorbability
EP1858488B2 (en) 2005-03-14 2022-07-20 Wyeth LLC Tigecycline compositions and methods of preparation
EP1954253A4 (en) * 2005-06-08 2011-07-27 Elan Pharma Int Ltd NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
JP2007106684A (ja) * 2005-10-11 2007-04-26 Sawai Pharmaceutical Co Ltd 抗菌性医薬組成物
EP1952803A1 (en) 2007-01-23 2008-08-06 KTB-Tumorforschungs GmbH Solid pharmaceutical dosage form containing hydrogenated phospholipids
WO2010066593A1 (en) * 2008-12-08 2010-06-17 F. Hoffmann-La Roche Ag Combined drug administration
CN103781478A (zh) * 2011-06-24 2014-05-07 艾森达制药有限公司 用以改善酯类前药吸收率的方法与改良的药学组合物
KR101561963B1 (ko) * 2013-05-23 2015-10-22 영진약품공업 주식회사 세프디토렌 피복실의 신규 결정 형태 및 이의 제조 방법
EP3244879A1 (en) * 2015-01-16 2017-11-22 Ögün, Yusuf Toktamis Cefditoren pivoxil compositions with improved stability and production methods thereof
CN110143957B (zh) * 2019-06-20 2020-12-25 重庆医药高等专科学校 头孢妥仑匹酯开环物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58487B1 (en) 1984-09-07 1993-09-22 Kaisha Maiji Seika New cephalosporin compounds and the production thereof
JPS6216431A (ja) * 1985-07-15 1987-01-24 Nakanishi Michio 医薬組成物
JPS62205088A (ja) 1986-03-03 1987-09-09 Meiji Seika Kaisha Ltd 新規セフエム化合物
US5651991A (en) 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
WO1990015609A1 (en) * 1989-06-15 1990-12-27 Med-Tal, Inc. Prevention and treatment of microbial infection by phosphoglycerides
JP2785981B2 (ja) 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
US5319116A (en) 1992-02-12 1994-06-07 Gary Viole Lecithin fractions and dilutions, methods for their preparation and pharmacological uses thereof
US6113921A (en) 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
JPH0717866A (ja) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
JPH0840907A (ja) 1994-08-03 1996-02-13 Meiji Seika Kaisha Ltd セファロスポリン注射剤
AR004014A1 (es) 1995-10-13 1998-09-30 Meiji Seika Kaisha Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion
AU4892897A (en) 1996-09-17 1998-04-14 Amur Pharmaceuticals, Inc. Phospholipid drug derivatives
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
ES2153786B1 (es) * 1999-06-10 2001-10-16 S A L V A T Lab Sa Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis.

Also Published As

Publication number Publication date
EP1401402B1 (en) 2016-09-07
CA2449002C (en) 2011-08-16
MXPA03010945A (es) 2004-02-27
EP1401402A4 (en) 2006-12-06
WO2002096354A2 (en) 2002-12-05
JP2005515155A (ja) 2005-05-26
CA2449002A1 (en) 2002-12-05
WO2002096354A3 (en) 2003-03-20
EP1401402A2 (en) 2004-03-31

Similar Documents

Publication Publication Date Title
US20030060451A1 (en) Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
US5952383A (en) Pharmaceutical composition for oral delivery
US8343543B2 (en) Lipase inhibiting composition
EP0287198B1 (en) Mixtures of polar and neutral lipids for protecting the gastronointestinal tract
KR102180667B1 (ko) 위장관을 따라 약물을 표적화 방출하기 위한 pH 감응성 담체, 그로부터의 조성물, 및 이들의 제조 및 사용 방법
CA2405360A1 (en) Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
HK1049798A1 (en) Solid lipid formulations
CA2449002C (en) Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin
JP2002501015A (ja) リーシュマニア症の治療における経口投与のためのミルテフォシンを含有する固形医薬品
AU2002257817A1 (en) Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester
MC1878A1 (fr) Compositions pharmaceutiques
AU731274B2 (en) Anticancer composition comprising a diaminotrifluoromethylpyridine derivative
JP5110460B2 (ja) アトピー性皮膚炎用外用剤及びその製造方法
US6506393B2 (en) Methods of treating protozoal diseases
EP0308349B1 (fr) Nouveau derivé de choline, son procédé de préparation et nouveaux médicaments le contenant
JPH0455167B2 (enExample)
JP5273440B2 (ja) 抗潰瘍剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090331

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20090625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090724

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090930

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20091204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110804

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110809

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20120412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120521

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120723

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150803

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees